TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03319940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent humanized IgG4 monoclonal antibody (mAb) with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS Mitigation Strategies
Description: Participants will be treated with one of the CRS mitigation strategies.
Study: NCT01795833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short text messages
Description: In addition to structured education on healthy lifestyle provided at baseline, subjects in the arm will receive short text messages containing educational, motivational and supportive content on diet, physical activity, and smoking (if appropriate) during the study period. The content will be appropriate to the stage of the transtheoretical model of behavioural change that the subject is in. This will be assessed by questionnaire at each visit to clinic.
Study: NCT00381940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC
Study: NCT00798720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: 400 mg by mouth once daily for days 1-14 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle
Study: NCT03154801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paramedical care
Description: Paramedical early detection of sexual dysfunction and sexual health counseling
Study: NCT03211260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EQUISTASI
Description: Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
Study: NCT00081224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study: NCT02863068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Sodium Nitrite
Description: Subjects will have 0.1 cm of 2% sodium nitrite cream applied per 1 cm2 of the total ulcerated area. Areas will be rounded to the nearest 1 cm2. If a subject has more than one ulcer, all of them will be treated with either study cream in this intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will have Placebo applied to total ulcerated area. If a subject has more than one ulcer, all of them will be treated with placebo in this intervention.
Study: NCT00986206

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker LPA and HE4
Description: Non Interventional Trial
Study: NCT02934490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh
Description: Meshes were made by Gynemech TM PS, (Johnson \& Johnson Shanghai Medical Equipment Co. SFDA registration No. 3460365, size 10 × 15cm)
Study: NCT00081224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study: NCT03322969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/DDP
Description: receiving the modified chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX/SOX
Description: receiving the original chemotherapy
Study: NCT03663868

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CC-Test
Description: Classification of the oocyte/embryo based on the gene expression pattern observed in the cumulus cells
Study: NCT00668954

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate Juice
Description: Group A drinks 8 oz. pomegranate juice/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice
Description: Group B drinks 8 oz. placebo juice/day for 12 weeks
Study: NCT03561090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3718
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-dose PPIs QD
Description: background therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard-dose PPIs QD
Description: background therapy
Study: NCT04150679

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: duodenojejunostomy access loop
Description: ROUX en Y hepaticojejunostomy with duodenojejunal anastomosis as permanent access

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepaticojejunostomy without access loop
Description: ROUX en Y hepaticojejunostomy without access loop
Study: NCT03362567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained Natural Apophyseal Glides
Description: Subjects in SNAGS group were treated with sustained natural apophyseal glides, twice weekly for six weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sustained Natural Apophyseal Glides
Description: Subjects in SNAGS group were treated with sustained natural apophyseal glides, twice weekly for six weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Cervical Traction
Description: subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Cervical Traction
Description: subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
Study: NCT03175302

Intervention type: BEHAVIORAL
Intervention: digital cognitive testing
Description: The digital testing is hypothesized to identify latent features for differentiating cognitively impaired presurgical patient subgroups

Intervention type: BEHAVIORAL
Intervention: digital cognitive testing
Description: The digital testing is hypothesized to identify latent features for differentiating cognitively impaired presurgical patient subgroups
Study: NCT04858958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib 160mg
Description: randomized to 160mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib 240mg
Description: randomized to 240mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib 240mg
Description: randomized to 240mg QD
Study: NCT01688466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 0.5 mg/day with and/or without Dose Escalation and 0.5 mg/day- 2.0 mg/day by mouth (PO) QD(every day) of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 0.5 mg/day with and/or without Dose Escalation and 0.5 mg/day- 2.0 mg/day by mouth (PO) QD(every day) of each 28 day cycle
Study: NCT01104610

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breas Vivo 40
Description: The Vivo 40 will be used either in CPAP mode, PSV mode without Target Volume or PSV mode with Target Volume

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breas Vivo 40
Description: The Vivo 40 will be used either in CPAP mode, PSV mode without Target Volume or PSV mode with Target Volume

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breas Vivo 40
Description: The Vivo 40 will be used either in CPAP mode, PSV mode without Target Volume or PSV mode with Target Volume
Study: NCT00402181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles and duration of each cycle is 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles and duration of each cycle is 28 days.
Study: NCT04552964

Intervention type: OTHER
Group type: OTHER
Intervention: Single arm
Description: Far Best Corrected Visual Acuity (BCVA) ; Intra-Ocular Pressure (IOP) assessment ; Fundus examination ; Automated visual field ; Slit lamp examination ; Pregnancy test ; Patient Satisfaction Questionnaire
Study: NCT03607929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: optimal
Description: Physiological Saline Solution
Study: NCT00081224

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study: NCT02401659

Intervention type: DEVICE
Intervention: CareLinK

Intervention type: DEVICE
Intervention: CareLinK
Study: NCT01513720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Tablets 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Tablets 200 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal®
Description: Lamictal® 200 mg Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamictal®
Description: Lamictal® 200 mg Tablets
Study: NCT01985529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT03135054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib is an oral FLT3 receptor tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine Mepesuccinate Injection
Description: Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
Study: NCT01473433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericardial adipose pedicle (adiFLAP) transposition.
Description: Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure. A non-revascularizable area will be considered whenever a transmural necrosis is detected by means of gadolinium contrast using MRI.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
Study: NCT00502970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 16 weeks Interferon Tiw with Ribavirin
Description: 16 weeks Interferon Tiw

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24 weeks Interferon
Description: 24 weeks Interferon Tiw with Ribavirin
Study: NCT03139578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test 8.5BC
Description: senofilcon A contact lenses with 8.5 base curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test 8.5BC
Description: senofilcon A contact lenses with 8.5 base curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test 8.5BC
Description: senofilcon A contact lenses with 8.5 base curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test 8.5BC
Description: senofilcon A contact lenses with 8.5 base curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test 9.0BC
Description: senofilcon A contact lenses with 9.0 base curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test 9.0BC
Description: senofilcon A contact lenses with 9.0 base curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test 9.0BC
Description: senofilcon A contact lenses with 9.0 base curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test 9.0BC
Description: senofilcon A contact lenses with 9.0 base curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control 8.5BC
Description: narafilcon A contact lenses with 8.5 base curve
Study: NCT03607929

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: variability
Description: Other solutions
Study: NCT01040325

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TD Vaccine System
Description: TD Vaccine System Containing Placebo Product
Study: NCT03086720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite
Description: Application of 10% sodium hypochlorite (60 seconds) after the etching procedure and before the adhesive system.
Study: NCT04681612

Intervention type: DIAGNOSTIC_TEST
Intervention: MSNA
Description: Assessed via Muscle Microneurography during the first 14 days of the acute phase.~Indices: busts/min, busts/100bpm

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Rate Variability
Description: Assessed via 24hr ECG monitoring during the first 14 days of the acute phase. Indices: Time-domain, Frequency-domain, Non-linear
Study: NCT03086720

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
Study: NCT02856074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prise de sang

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life questionnaire
Study: NCT03726190

Intervention type: PROCEDURE
Intervention: Oblique Lateral Lumbar Fusion
Description: Oblique lateral lumbar interbody fusion (OLLIF) is a lumbar spinal fusion. OLLIF is performed with the patient in the prone position and employs an oblique lateral approach that enables the instrumentation to pass through Kambin's triangle which is defined as the space between the exiting nerve, the superior border of the caudal vertebra, and the superior articulating process of the inferior facet. This approach may be performed without direct visualization, guided by electrophysiological monitoring and biplanar fluoroscopy. During the approach, a blunt probe is used to make contact with the disc, followed by a series of gentle dilations. Discectomy is performed through a 10-mm access portal. The cage is inserted under continued electrophysiological monitoring and fluoroscopy.
Study: NCT04681612

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Pressure Variability
Description: Assessed via Ambulatory BPM during the first 14 days of the acute phase. Indices: SD, wSD, ARV, CV
Study: NCT03281421

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: The manual therapy intervention, through the technique of mobilization with movement in the ankle joint (following the specific sense direction of the group), will be performed in a protocol that consists of four sets of five repetitions, with rest time between series of one minute.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: The manual therapy intervention, through the technique of mobilization with movement in the ankle joint (following the specific sense direction of the group), will be performed in a protocol that consists of four sets of five repetitions, with rest time between series of one minute.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: The manual therapy intervention, through the technique of mobilization with movement in the ankle joint (following the specific sense direction of the group), will be performed in a protocol that consists of four sets of five repetitions, with rest time between series of one minute.
Study: NCT04681612

Intervention type: DIAGNOSTIC_TEST
Intervention: CMR
Description: Cardiac Magnetic Resonance during the first 14 days of the acute phase. Assessment of oedema, Late Gadolinium Enhancement ischaemic pattern. Assessment of cardiac function parameters

Intervention type: DIAGNOSTIC_TEST
Intervention: History, Lab, clinical and hemodynamic parameters
Description: 1. Description of event, 2. Risk factors, 3. Medical history, 4. ECG parameters, 5. ECHO parameters, 6. Hemodynamic parameters of acute phase and hospitalization, 7. Coronary angiogram paraemeters, 7. Complete lab parameter assessment, 8. Thrombofilia assessment, 9. SF-12 QoL and Anxiety and Depression Scale (HADS) questionnaires
Study: NCT02633800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab
Description: Patritumab initial loading dose is 18 mg/kg IV over 60 minutes followed by a maintenance dose of 9 mg/kg IV over 60 minutes (± 10 minutes) every three weeks
Study: NCT01001897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
Study: NCT02633800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400 mg/mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 400 mg/mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at 100 mg/m\^2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin at 100 mg/m\^2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles
Study: NCT01001897

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
Study: NCT00800098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: herbal topical cream
Study: NCT02633800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match patritumab
Study: NCT04585932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC
Study: NCT01685307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test meal
Description: test meal is 150 g of beef cooked either at moderate or high intensity. Proteins are intrinsically labelled with 15N.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test meal
Description: test meal is 150 g of beef cooked either at moderate or high intensity. Proteins are intrinsically labelled with 15N.
Study: NCT03139578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control 8.5BC
Description: narafilcon A contact lenses with 8.5 base curve
Study: NCT04585932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00800098

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: herbal topical cream
Study: NCT04585932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study: NCT03565510

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Protein Diet
Description: The high-protein diet is composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement.
Study: NCT03139578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control 8.5BC
Description: narafilcon A contact lenses with 8.5 base curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control 8.5BC
Description: narafilcon A contact lenses with 8.5 base curve
Study: NCT04371783

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Immediate FET
Description: FET is performed in the first menstrual cycle following the stimulated IVF cycle

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed FET
Description: FET is performed in the second menstrual cycle following the stimulated IVF cycle